Amanda Lanier

Graphite’s nula-cel perseveres as Kamau emerges from stealth

Dec. 8, 2023

Following a strategic transaction with Graphite Bio Inc., Kamau Therapeutics is emerging from stealth with sickle cell treatment nulabeglogene autogedtemcel (nula-cel). Kamau received an option to acquire all of Graphite’s genome editing assets, including a platform technology that integrates precision DNA repair using homology directed repair and CRISPR/Cas9, as well as the autologous CRISPR/Cas9 gene corrected CD34+ cell product nula-cel, which offers a potential cure for sickle cell disease derived from the patient's cells.

Biopharma financings November 2023

Biopharma funding hits $5.65B in November, with 18% increase YTD

Dec. 8, 2023

By Amanda Lanier

In November, the biopharma industry raised $5.65 billion in total financings. While down from $11.6 billion tracked by BioWorld in October, overall financings are tracking ahead of last year. Biopharma funding has maintained an average of $6.1 billion per month in 2023, surpassing the $5.07 billion monthly average throughout 2022.

Med-tech financings November 2023

Med-tech financings mark YOY decline, November sees more than $1B raised

Dec. 8, 2023

By Amanda Lanier

Med-tech financings surpassed $1 billion again in November, with transactions totalling $1.02 billion for the month. Though a decline from the $1.23 billion raised in October, the value is up from September’s $645.75 million.

Biopharma nonprofit deals and grants October 2023

Biopharma grants see 75% growth YOY, while nonprofit deals decline

Dec. 5, 2023

By Amanda Lanier

Biopharma grants have sustained the upward trajectory noted in August, ending October up nearly 75% compared to the corresponding period last year. In contrast, nonprofit deal value has continued its year-over-year decline, marked by a more than 90% decrease in value.

BioWorld Neurological Diseases Index (BNDI)

Volatility defines neurological disease stocks in 2023

Dec. 4, 2023

By Amanda Lanier

Clinical data disappointments and third-quarte results cast a shadow on the BioWorld Neurological Diseases Index, closing November with an 18.37% year-to-date decline. This marks a slight improvement from its low point in October, down 23.79%, in contrast to the previous year’s upward trend, which it concluded with an 18.24% increase.

Biopharma nonprofit deals and grants October 2023

Biopharma grants see 75% growth YOY, while nonprofit deals decline

Dec. 1, 2023

By Amanda Lanier

Biopharma grants have sustained the upward trajectory noted in August, ending October up nearly 75% compared to the corresponding period last year. In contrast, nonprofit deal value has continued its year-over-year decline, marked by a more than 90% decrease in value.

Health professional holding stethoscope with health icons

Biopharma clinical updates October 2023

Clinical trial updates up nearly 5% through October

Nov. 28, 2023

By Amanda Lanier

Clinical trial updates for the period of January to October 2023 saw an increase of 4.6% compared to the same time period last year. Comparatively, clinical data from January to September 2023 was up 1.79% compared to the same period last year.

Biopharma clinical updates October 2023

Clinical trial updates up nearly 5% through October

Nov. 22, 2023

By Amanda Lanier

Clinical trial updates for the period of January to October 2023 saw an increase of 4.6% compared to the same time period last year. Comparatively, clinical data from January to September 2023 was up 1.79% compared to the same period last year.

BioWorld Drug Developers Index (BDDI)

Blueprint Medicines up on Q3 results amidst broader drug developer decline

Nov. 22, 2023

By Amanda Lanier

BioWorld’s Drug Developers Index continued to fall in October, down 31.4% for the year, compared to September when it ended down 22.8%. Among the 30 stocks tracked, only five saw gains, with the remaining 25 experiencing declines, aligning with the year’s overall trend through Nov. 16. In March, the index experienced a 12.56% drop, stayed around negative 12% through July, and has faced steady declines since.

Biopharma regulatory actions and approvals October 2023

US FDA approves 27 drugs in October, marking highest month since 2020

Nov. 20, 2023

By Amanda Lanier

In October, U.S. FDA approvals experienced a significant upswing, reaching a total of 27 for the month, a 92.86% increase from 14 approvals recorded by BioWorld in September. In the initial 10 months of this year, FDA approvals hit 155, an increase of 22.05% from the 127 drugs approved last year, although approvals are down from 2018-2021. Approved new molecular entities are at 29 in 2023, up from 28 in the corresponding period last year but a decline from 2017-2021.